Literature DB >> 10765928

CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndromes.

G Coakley1, M Iqbal, D Brooks, G S Panayi, J S Lanchbury.   

Abstract

OBJECTIVE: To investigate the ability of CD8+,CD57+ large granular lymphocytes (LGL) from normal individuals and from Felty's syndrome (FS) or LGL syndrome patients to suppress allogeneic neutrophil precursor development.
METHODS: Six FS patients, 5 LGL syndrome patients, and 13 elderly controls were studied. CD8+,CD57+ T cells were cocultured with cord blood-derived stem cells, and percentage inhibition was calculated. Recombinant chemokines and Fas-stimulating molecules were used in separate cultures to address possible mechanisms of suppression. Proliferation after stimulation with interleukin-2 (IL-2) and anti-CD3 was assessed.
RESULTS: Significant (79%) suppression of colony-forming unit-granulocyte-macrophage (CFU-GM) by the CD8+,CD57+ subset was shown by 1 FS patient. None of the CD8+,CD57+ cells from LGL syndrome patients had any effect. Six of 13 controls studied showed >40% inhibition of CFU-GM, and all but 2 showed at least some suppression. The suppressive effect was not mediated by Fas/Fas ligand interactions or by the chemokines macrophage inhibitory protein 1alpha or IL-8. LGL from both patients and controls were largely CD28- and had reduced proliferative capacity.
CONCLUSION: In a subset of FS patients, expansion of CD8+,CD57+ T cells in the bone marrow may be responsible for neutropenia by suppressing neutrophil precursors. This effect is also seen with normal LGL, which are likely to have an important function in neutrophil homeostasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10765928     DOI: 10.1002/1529-0131(200004)43:4<834::AID-ANR14>3.0.CO;2-H

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

1.  Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy.

Authors:  Athina Theodoridou; Charalambos Kartsios; Efthalia Yiannaki; Dimitra Markala; Lucas Settas
Journal:  Rheumatol Int       Date:  2006-08-25       Impact factor: 2.631

2.  Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma.

Authors:  Kenji Fukuno; Hisashi Tsurumi; Nobuhiro Ando; Nobuhiro Kanemura; Hideko Goto; Shinobu Tanabashi; Kiyonao Okamoto; Hisataka Moriwaki
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

3.  Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient.

Authors:  Mariano Marrodan; Julia Laviano; Sofía Oneto; Fabricio M Reino; Ricardo Delorme; Florencia Fornillo; José Férnandez; Jorge Correale
Journal:  Neurol Sci       Date:  2021-06-01       Impact factor: 3.307

Review 4.  [T-large granular lymphocyte leukaemia. An important differential diagnosis to Felty's syndrome].

Authors:  F Moosig; R Schoch; M Kneba
Journal:  Z Rheumatol       Date:  2006-09       Impact factor: 1.372

5.  Autoantibodies against granulocyte-macrophage colony stimulating factor and interleukin-3 are rare in patients with Felty's syndrome.

Authors:  B Hellmich; A Ciaglo; H Schatz; G Coakley
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

6.  Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia.

Authors:  Sanjay R Mohan; Michael J Clemente; Manuel Afable; Heather N Cazzolli; Nelli Bejanyan; Marcin W Wlodarski; Alan E Lichtin; Jaroslaw P Maciejewski
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

7.  Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia.

Authors:  Marcin W Wlodarski; Zachary Nearman; Anna Jankowska; Nina Babel; Jennifer Powers; Patrick Leahy; Hans-Dieter Volk; Jaroslaw P Maciejewski
Journal:  J Leukoc Biol       Date:  2007-12-17       Impact factor: 4.962

8.  Differential expression of NK receptors CD94 and NKG2A by T cells in rheumatoid arthritis patients in remission compared to active disease.

Authors:  Ceara E Walsh; Elizabeth J Ryan; Cliona O'Farrelly; Lucy Golden-Mason; Oliver FitzGerald; Douglas J Veale; Barry Bresnihan; Ursula Fearon
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

Review 9.  Primary and secondary autoimmune neutropenia.

Authors:  Franco Capsoni; Piercarlo Sarzi-Puttini; Alberto Zanella
Journal:  Arthritis Res Ther       Date:  2005-08-31       Impact factor: 5.156

Review 10.  Dysregulation of CD8+ lymphocyte apoptosis, chronic disease, and immune regulation.

Authors:  Karen L Wood; Homer L Twigg; Andrea I Doseff
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.